At booth 602 SCHOTT will be showcasing a whole range of new packaging solutions – starting from glass vials that help pharma companies to prevent delamination to ready to use solutions that enable lyophilization of nested glass containers. In order to ensure a smooth integration into existing customers’ processes, SCHOTT has been working on both of these topics together with its customers and filling line manufacturers.

SCHOTT Vials Delamination Controlled represent an improved packaging product for pharmaceutical companies interested in lowering the risk of delamination. Based on a more homogeneous inner surface and higher chemical stability SCHOTT combines improved container properties with the so called SCHOTT Delamination Quicktest: a patented quantitative test method that allows for the measurement and documentation of this lower tendency to delamination. SCHOTT Vials DC thus represent an interesting solution for pharmaceutical companies interested in lowering the risk of delamination by selecting an improved packaging product – not only for new drug products, but also for medications that are already well established in the marketplace. Dr. Bernhard Hladik, Head of Product Management, will be explaining SCHOTT’s new product in his presentation "Delamination – Root cause and solutions" on February 12, 4:45 – 5:00 PM.

With adaptiQ™, SCHOTT has unveiled a new concept of ready-to-use pharmaceutical vials that has been modified in close cooperation with filling line manufacturers to meet the process requirements of the pharmaceutical industry. SCHOTT adaptiQ™ consists of a nest and tub configuration that allows for as many as 100 vials to be securely fixed inside a holder (nest) and delivered to the pharmaceutical company packaged in a sterile container. What makes SCHOTT’s innovation unique is its patented nest design; unlike all of the other solutions currently on the market, adaptiQ™ allows for vials to be subjected to all of the processing steps while inside the nest, even freeze-drying, weighing and crimping for the first time ever. Besides simplifying the process, the main focus is on protecting the glass containers, which can no longer come into contact with each other or be scratched by machine components.

SCHOTT will also be displaying its broad range of prefillable syringes – an area where the company intends to achieve further growth. To highlight SCHOTT’s commitment the company now markets all glass syringes under the umbrella of the new brand name syriQTM. The offerings range from 0.5 to 3 Milliliter (ml) products, suitable for a broad variety of applications like heparin, vaccines, biotech, and special applications. With regard to polymer syringes, marketed under the brand name SCHOTT TopPac®, the company has recently completed its portfolio of large volume syringes for intensive care which now includes the entire range of 10 ml, 20 ml, and 50 ml formats.

In addition, SCHOTT pharma services will be presenting its range of analytical laboratory services on primary pharmaceutical packaging. The focus here will be on new analytical methods for use with delamination and extractables and leachables.